Every 10-Q that Nautilus Biotechnolgy, Inc. (NAUT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NAUT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAUT filings page.
Nautilus Biotechnology, Inc. reported $234,000 in revenue and a $15.636 million net loss for the three months ended September 30, 2026; the net loss was 15% higher than in the year-earlier quarter. Revenue comprised grant revenue from The Michael J. Fox Foundation and Early Access Program service revenue. For the nine months, revenue was $424,000 and net loss was $44.802 million, compared with $45.220 million a year earlier.
Cash, cash equivalents and investments totaled $114.3 million at September 30, 2026, and the company believes these resources will fund operations for at least the next 12 months following issuance of its financial statements. In September, Nautilus entered a sales agreement with TD Cowen under which it may sell up to $125.0 million of common stock through an at-the-market program; it made no sales under the agreement during the nine months ended September 30, 2026.
The Voyager platform remains under development. The broadscale assay has not advanced sufficiently to support general availability in 2027 to target specifications, and Nautilus plans to reallocate resources toward proteoform applications. The company expects to open platform pre-orders in early 2027, with instrument shipments beginning in mid-2027.
Nautilus Biotechnology, a development-stage proteomics company, reported revenue of $0.2 million for the six months ended June 30, 2026, mainly from a Michael J. Fox Foundation grant and early access services. Net loss was $29.2 million, modestly better than $31.6 million a year earlier, as research and development and selling, general and administrative expenses declined 12% and 9%, respectively.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled $84.0 million, and cash, cash equivalents and investments were $129.2 million. Management believes this will fund operations for at least 12 months. The company has a $125.0 million at-the-market equity program and a $300.0 million shelf registration. Nautilus continues developing its Nautilus Voyager proteomics platform, has launched an Iterative Mapping Early Access Program focused on Tau and other proteoforms, and plans a phased commercial launch with pre-orders in early 2027 and instrument shipments in mid-2027.
Nautilus Biotechnology reported a Q1 2026 net loss of $14.7 million, an improvement from $16.6 million a year earlier, as it continues developing its Nautilus Voyager proteomics platform with no product revenue yet. Research and development expenses fell to $9.7 million and selling, general and administrative costs declined to $6.4 million, reflecting prior cost reductions.
The company held $95.9 million in cash, cash equivalents and short‑term investments and $143.4 million including long‑term investments as of March 31, 2026, and believes this will fund operations for at least the next twelve months while it advances its Early Access Program and phased commercial launch planned for 2026–2027.
Nautilus Biotechnology (NAUT) filed its Q3 2025 10‑Q, reporting continued development-stage operations with no product revenue and a narrower quarterly loss. Net loss was $13.6 million for the quarter and $45.2 million for the nine months. Operating expenses decreased to $15.5 million in Q3, driven by lower R&D ($9.6 million) and G&A ($5.9 million), reflecting cost optimizations and prior workforce reductions.
As of September 30, 2025, the company held $131.4 million in cash, cash equivalents, and short‑term investments, and stated these resources are sufficient to fund operations for at least the next twelve months. Total assets were $200.9 million and stockholders’ equity was $169.1 million. Interest income was $1.9 million in Q3, down year over year on lower balances and yields.
Nautilus remains in the collaboration phase for its proteomics platform and expects early access offerings in the first half of 2026 (including Tau assays) with a broader launch targeted for late 2026. Shares outstanding were 126,305,122 as of October 23, 2025.